183 related articles for article (PubMed ID: 22304717)
1. Structure-activity relationships of glutamate carboxypeptidase II (GCPII) inhibitors.
Ferraris DV; Shukla K; Tsukamoto T
Curr Med Chem; 2012; 19(9):1282-94. PubMed ID: 22304717
[TBL] [Abstract][Full Text] [Related]
2. Molecular modeling of the interactions of glutamate carboxypeptidase II with its potent NAAG-based inhibitors.
Rong SB; Zhang J; Neale JH; Wroblewski JT; Wang S; Kozikowski AP
J Med Chem; 2002 Sep; 45(19):4140-52. PubMed ID: 12213057
[TBL] [Abstract][Full Text] [Related]
3. Synthesis of urea-based inhibitors as active site probes of glutamate carboxypeptidase II: efficacy as analgesic agents.
Kozikowski AP; Zhang J; Nan F; Petukhov PA; Grajkowska E; Wroblewski JT; Yamamoto T; Bzdega T; Wroblewska B; Neale JH
J Med Chem; 2004 Mar; 47(7):1729-38. PubMed ID: 15027864
[TBL] [Abstract][Full Text] [Related]
4. Structural characterization of P1'-diversified urea-based inhibitors of glutamate carboxypeptidase II.
Pavlicek J; Ptacek J; Cerny J; Byun Y; Skultetyova L; Pomper MG; Lubkowski J; Barinka C
Bioorg Med Chem Lett; 2014 May; 24(10):2340-5. PubMed ID: 24731280
[TBL] [Abstract][Full Text] [Related]
5. Design of highly potent urea-based, exosite-binding inhibitors selective for glutamate carboxypeptidase II.
Tykvart J; Schimer J; Jančařík A; Bařinková J; Navrátil V; Starková J; Šrámková K; Konvalinka J; Majer P; Šácha P
J Med Chem; 2015 May; 58(10):4357-63. PubMed ID: 25923815
[TBL] [Abstract][Full Text] [Related]
6. Expression of glutamate carboxypeptidase II in human brain.
Sácha P; Zámecník J; Barinka C; Hlouchová K; Vícha A; Mlcochová P; Hilgert I; Eckschlager T; Konvalinka J
Neuroscience; 2007 Feb; 144(4):1361-72. PubMed ID: 17150306
[TBL] [Abstract][Full Text] [Related]
7. Carborane-containing urea-based inhibitors of glutamate carboxypeptidase II: Synthesis and structural characterization.
Youn S; Kim KI; Ptacek J; Ok K; Novakova Z; Kim Y; Koo J; Barinka C; Byun Y
Bioorg Med Chem Lett; 2015 Nov; 25(22):5232-6. PubMed ID: 26459214
[TBL] [Abstract][Full Text] [Related]
8. N-acetylaspartylglutamate (NAAG) and glutamate carboxypeptidase II: An abundant peptide neurotransmitter-enzyme system with multiple clinical applications.
Neale JH; Yamamoto T
Prog Neurobiol; 2020 Jan; 184():101722. PubMed ID: 31730793
[TBL] [Abstract][Full Text] [Related]
9. Glutamate carboxypeptidase II: an overview of structural studies and their importance for structure-based drug design and deciphering the reaction mechanism of the enzyme.
Pavlícek J; Ptácek J; Barinka C
Curr Med Chem; 2012; 19(9):1300-9. PubMed ID: 22304708
[TBL] [Abstract][Full Text] [Related]
10. Still NAAG'ing After All These Years: The Continuing Pursuit of GCPII Inhibitors.
Vornov JJ; Hollinger KR; Jackson PF; Wozniak KM; Farah MH; Majer P; Rais R; Slusher BS
Adv Pharmacol; 2016; 76():215-55. PubMed ID: 27288079
[TBL] [Abstract][Full Text] [Related]
11. Structure of glutamate carboxypeptidase II, a drug target in neuronal damage and prostate cancer.
Mesters JR; Barinka C; Li W; Tsukamoto T; Majer P; Slusher BS; Konvalinka J; Hilgenfeld R
EMBO J; 2006 Mar; 25(6):1375-84. PubMed ID: 16467855
[TBL] [Abstract][Full Text] [Related]
12. Rational design of urea-based glutamate carboxypeptidase II (GCPII) inhibitors as versatile tools for specific drug targeting and delivery.
Tykvart J; Schimer J; Bařinková J; Pachl P; Poštová-Slavětínská L; Majer P; Konvalinka J; Šácha P
Bioorg Med Chem; 2014 Aug; 22(15):4099-108. PubMed ID: 24954515
[TBL] [Abstract][Full Text] [Related]
13. Human glutamate carboxypeptidase II inhibition: structures of GCPII in complex with two potent inhibitors, quisqualate and 2-PMPA.
Mesters JR; Henning K; Hilgenfeld R
Acta Crystallogr D Biol Crystallogr; 2007 Apr; 63(Pt 4):508-13. PubMed ID: 17372356
[TBL] [Abstract][Full Text] [Related]
14. Deletion of the glutamate carboxypeptidase II gene in mice reveals a second enzyme activity that hydrolyzes N-acetylaspartylglutamate.
Bacich DJ; Ramadan E; O'Keefe DS; Bukhari N; Wegorzewska I; Ojeifo O; Olszewski R; Wrenn CC; Bzdega T; Wroblewska B; Heston WD; Neale JH
J Neurochem; 2002 Oct; 83(1):20-9. PubMed ID: 12358725
[TBL] [Abstract][Full Text] [Related]
15. Glutamate carboxypeptidase II does not process amyloid-β peptide.
Sedlák F; Šácha P; Blechová M; Březinová A; Šafařík M; Šebestík J; Konvalinka J
FASEB J; 2013 Jul; 27(7):2626-32. PubMed ID: 23525279
[TBL] [Abstract][Full Text] [Related]
16. Structural basis of interactions between human glutamate carboxypeptidase II and its substrate analogs.
Barinka C; Hlouchova K; Rovenska M; Majer P; Dauter M; Hin N; Ko YS; Tsukamoto T; Slusher BS; Konvalinka J; Lubkowski J
J Mol Biol; 2008 Mar; 376(5):1438-50. PubMed ID: 18234225
[TBL] [Abstract][Full Text] [Related]
17. Glutamate carboxypeptidase II in diagnosis and treatment of neurologic disorders and prostate cancer.
Bařinka C; Rojas C; Slusher B; Pomper M
Curr Med Chem; 2012; 19(6):856-70. PubMed ID: 22214450
[TBL] [Abstract][Full Text] [Related]
18. Regulation of glutamate carboxypeptidase II hydrolysis of N-acetylaspartylglutamate (NAAG) in crayfish nervous tissue is mediated by glial glutamate and acetylcholine receptors.
Urazaev AK; Grossfeld RM; Lieberman EM
J Neurochem; 2005 May; 93(3):605-10. PubMed ID: 15836619
[TBL] [Abstract][Full Text] [Related]
19. S1 pocket of glutamate carboxypeptidase II: a new binding site for amyloid-β degradation.
Lee SK; Kim H; Cheong YH; Kim MJ; Jo SA; Youn HS; Park SI
Biochem Biophys Res Commun; 2013 Sep; 438(4):765-71. PubMed ID: 23891752
[TBL] [Abstract][Full Text] [Related]
20. Design of composite inhibitors targeting glutamate carboxypeptidase II: the importance of effector functionalities.
Novakova Z; Cerny J; Choy CJ; Nedrow JR; Choi JK; Lubkowski J; Berkman CE; Barinka C
FEBS J; 2016 Jan; 283(1):130-43. PubMed ID: 26460595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
